A large, real-world comparative analysis evaluated 1-year clinical and safety outcomes among patients with chronic lymphocytic leukemia receiving venetoclax-based versus Bruton's tyrosine kinase...
Ibrutinib, the first-generation Bruton tyrosine kinase inhibitor, has well-documented cardiovascular effects that influence treatment decisions for patients with chronic lymphocytic leukemia. This quiz...
Ibrutinib, the first-generation Bruton tyrosine kinase inhibitor, has well-documented cardiovascular effects that influence treatment decisions for patients with chronic lymphocytic leukemia. This quiz...
Core needle biopsy accuracy varies by lymphoma subtype. Which one yields the highest diagnostic sensitivity? Test your knowledge of hematologic pathology.
Richter transformation of chronic lymphocytic leukemia carries poor outcomes with traditional therapies, but emerging treatments may improve survival. Test your knowledge of prognosis by taking this quick...
How well do you understand the latest findings on fixed-duration acalabrutinib–venetoclax regimens in untreated chronic lymphocytic leukemia? Take this quiz to find out!
The survival outcomes for patients diagnosed with this chronic lymphocytic leukemia complication have remained poor for decades. Can you name the complication? Take the quiz to find out!
Daniel Lenihan, MD, FACC, FESC, FIC-OS, a cardio-oncologist and founder of the International Cardio-Oncology Society, discusses cardiovascular risks associated with Bruton's tyrosine kinase inhibitors in...